Furthermore, clinical studies have shown a strong correlation between the cytoplasmic localization of METTL3 and GC progression, suggesting that METTL3’s subcellular distribution may serve as a prognostic marker for cancer patients (Wei et al., 2022). Here, METTL3 is linked to cancer.